Celcuity Highlights Gedatolisib Breast Cancer Data, Near-Term Mutant Readout at Leerink Conference [Yahoo! Finance]
Celcuity Inc. (CELC)
Last celcuity inc. earnings: 3/12 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
celcuity.com/home/investors
Company Research
Source: Yahoo! Finance
breast cancer — the triplet (gedatolisib + palbociclib + fulvestrant) showed median PFS of 9.3 vs 2 months with a hazard ratio of 0.24, supporting the company's thesis that comprehensive PI3K/mTOR inhibition can benefit patients regardless of PIK3CA status. The company expects a near-term readout from the PIK3CA-mutant cohort "end of this quarter, sometime next quarter," citing early phase Ib signals of ~14.5–19 months median PFS and noting that ~10 months would be statistically meaningful versus prior controls (alpelisib + fulvestrant) and compares favorably with other regimens. Celcuity is preparing for commercialization and regulatory milestones — targeting a mid-July PDUFA date, hiring a sales force beginning in Q2, viewing IV administration as commercially acceptable, and pausing ex-U.S. partnering talks pending the mutant-cohort data. Interested in Celcuity, Inc.? Here are five stocks we like better. 3 Stocks You'll Wish You Bought Before 2026 Celcuity (NASDAQ:CELC) Ch
Show less
Read more
Impact Snapshot
Event Time:
CELC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CELC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CELC alerts
High impacting Celcuity Inc. news events
Weekly update
A roundup of the hottest topics
CELC
News
- Columbia Flexible Capital Income Fund Q4 2025 Commentary [Seeking Alpha]Seeking Alpha
- Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and Webcast/Conference CallGlobeNewswire
- Celcuity (CELC) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $122.00 price target on the stock.MarketBeat
- What Celcuity (CELC)'s Gedatolisib Phase 3 Progression-Free Survival Data Means For Shareholders [Yahoo! Finance]Yahoo! Finance
- Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug [Yahoo! Finance]Yahoo! Finance
CELC
Earnings
- 11/12/25 - Beat
CELC
Sec Filings
- 3/9/26 - Form SCHEDULE
- 2/17/26 - Form SCHEDULE
- 2/17/26 - Form SCHEDULE
- CELC's page on the SEC website